期刊文献+

舒尼替尼治疗转移性肾癌的疗效及安全性评价

下载PDF
导出
摘要 目的探讨舒尼替尼治疗转移性肾癌的有效性及安全性,并总结相关临床使用经验。方法选取我院2010年1月至2014年3月治疗的肾癌患者28例,对患者给予舒尼替尼治疗,连续用药1个月后停药2周,以6周作为一个循环。结果治疗一段时间后对患者身体状况进行观察,同时对本次治疗进行相应评价,本次治疗治愈患者1例,部分缓解6例,稳定20例,1例处于病情进展状态。治疗期间观察到患者出现了一些不良反应症状,例如高血压、口腔溃疡、腹泻、血红蛋白减少等。结论舒尼替尼对于转移性肾癌治疗效果优良,可以显著提高疾病控制率,其所产生的不良反应患者尚可接受,对临床治疗十分有利。
作者 饶胜
出处 《湖北科技学院学报(医学版)》 2015年第1期30-31,共2页 Journal of Hubei University of Science and Technology(Medical Sciences)
  • 相关文献

参考文献5

  • 1Siegel R,Ward E,Brawley 0,et al.Cancer statistics,2011:the impact of eliminating socioeconomic and racial disparities on premature cancer deaths[J].CA Cancer J Clin,2011,61(4):212. 被引量:1
  • 2Procopio G,Verzoni E,lacovelli R,et al.Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma?Efficacy data from a retrospective analysis of 7 cases[J].Clin Exp Nephrol,2012,16(3):464. 被引量:1
  • 3秦叔逵,金杰,王金万.舒尼替尼一线治疗中国转移性肾细胞癌患者的单臂、开放、多中心、IV期临床研究中期分析[C].北京:2010,CSCO年会论文集,KI017. 被引量:1
  • 4施国海,姚旭东,张世林,戴波,张海梁,沈益君,朱耀,朱一平,马春光,肖文军,秦晓健,林国文,杨立峰,叶定伟.舒尼替尼治疗转移性非透明细胞肾癌的疗效观察[J].中华泌尿外科杂志,2011,32(10):711-713. 被引量:7
  • 5吴翔,于楠,高莹,李学松,黄立华,宋毅,龚侃,谌诚,虞巍,宋刚,赵峥,张争,张骞,王刚,何志嵩,周利群,金杰.舒尼替尼致转移性肾细胞癌患者甲状腺功能异常的临床分析[J].中华临床医师杂志(电子版),2011,5(3):11-14. 被引量:6

二级参考文献31

  • 1Badros AZ,Siegel E,Bodenner D,et al.Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.Am J Med,2002,112(5):412-413. 被引量:1
  • 2Stein EM,Rivera C.Transient thyroiditis after treatment with lenalidomide in a patient with metastatic renal cell carcinoma.Thyroid,2007,17(7):681-683. 被引量:1
  • 3Wang J,Milosveski V,Schramek C,et al.Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function.J Endocrinol,1998,157(1):5-12. 被引量:1
  • 4Kamba T,Tam BY,Hashizume H,et al.VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.Am J Physiol Heart Circ Physiol,2006,290(2):H560-576. 被引量:1
  • 5Wong E,Rosen LS,Mulay M,et al.Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.Thyroid,2007,17(4):351-355. 被引量:1
  • 6Tamaskar I,Bukowski R,Elson P,et al.Thyroid dysfunction test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.Ann Oncol,2008,19(2):265-268. 被引量:1
  • 7Laurberg P,Andersen S,Bülow Pedersen I,et al.Hypothyroidism in the elderly:pathophysiology,diagnosis and treatment.Drugs Aging,2005,22 (1):23-38. 被引量:1
  • 8Wolter P,Stefan C,Decallonne B,et al.The clinical implications of sunitinib-induced hypothyroidism:a prospective evaluation.Br J Cancer,2008,99(3):448-454. 被引量:1
  • 9Valentina B,Renato T,Alberto L,et al.The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients:A prospective single-center study.Urol Oncol,2010 Sep 28. 被引量:1
  • 10Motzer RJ,Michaelson MD,Redman BG,et al.Activity of SU11248,a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor,in Patients With Metastatic Renal Cell Carcinoma.J Clin Oncol,2006,24(1):16-24. 被引量:1

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部